Phase III study of Teprotumumab
Horizon Pharma (HZNP) reported top line results of its Phase III Teprotumumab clinical study for the treatment of TED on February 28, 2019. The Phase III trial was a confirmatory study of Phase II and was 21 weeks long, that included 83 patients across multiple clinical sites in the U.S., Germany, and Italy. Teprotumumab was tested against placebo and patients received eight intravenous infusions with 10mg/kg for the first injection and 20mg/kg afterwards.
Source: Investor Presentation, February 2019
The primary endpoint was a responder rate of ?